Close Menu

NEW YORK (GenomeWeb) – A team from Sweden, Belgium, and the UK has found evidence that an increasing number of androgen receptor splicing shifts and alterations in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) may be promising blood markers for treatment resistance and survival outcomes in advanced prostate cancer patients with TP53 mutation-free tumors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.